Bristol Myers Squibb Sotyktu long term data demonstrate durable efficacy, consistent safety for up to 3 years in moderate-to-severe Plaque Psoriasis Ruchika Sharma12 Oct 2023 12:50 PM ISTPrinceton: Bristol Myers Squibb has announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu...
Bristol Myers Squibb Sotyktu gets European Commission nod for adults with plaque psoriasis Ruchika Sharma30 March 2023 1:24 PM ISTSotyktu is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small...
FDA approves new oral treatment Sotyktu for psoriasis Dr. Kamal Kant Kohli13 Sept 2022 10:00 AM ISTThe US Food and drug administration has approved a new oral treatment Sotyktu for plaque psoriasis. In clinical trials, Sotyktu was more effective...
Bristol Myers Squibb bags USFDA approval for plaque psoriasis oral treatment Sotyktu Ruchika Sharma12 Sept 2022 1:29 PM ISTPsoriasis is a widely prevalent, chronic, systemic immune-mediated disease.
